Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D₃.
Inhibition of p38MAPK alpha/beta is known to enhance 1,25-dihydroxyvitamin (1,25D)-induced monocytic differentiation, but the detailed mechanism of this effect was not clear. We now show that the enhancement of differentiation becomes apparent with slow kinetics (12-24 h). Interestingly, the inhibition of p38MAPK alpha/beta by their selective inhibitor SB202190 (SB) leads to an upregulated expression of p38MAPK isoforms gamma and delta in 1,25D-treated AML cells, in cell lines and in primary culture. Although the expression and activating phosphorylations of p38MAPK alpha are also increased by an exposure of the cells to SB, its kinase activity is blocked by SB, as shown by reduced levels of phosphorylated Hsp27, a downstream target of p38MAPK alpha. A positive role of p38MAPKs in 1,25D-induced differentiation is shown by the inhibition of differentiation by antisense oligonucleotides to all p38MAPK isoforms. Other principal branches of MAPK pathways showed early (6 h) activation of MEK/ERK by SB, followed by activation of JNK1/2 pathway and enhanced expression and/or activation of PU.1, ATF-2 differentiation-related transcription factors. Taken together with previous reports, the results indicate that 1,25D-induced differentiation is enhanced by the activation of at least three branches of MAPK pathways (ERK1/2; p38MAPK gamma/delta; JNK1/2). This activation may result from the removal of feedback inhibition of an upstream regulator of those pathways, when p38MAPK alpha and beta are inhibited by SB.
Zhang
Jing
J
Department of Pathology and Laboratory Medicine, UMDNJ-New Jersey, Medical School, Newark, NJ 07103, USA.
Harrison
Jonathan S
JS
Studzinski
George P
GP
D000943:Antigens, Differentiation / Q000235:genetics / Q000378:metabolism; D002117:Calcitriol / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects* / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D048291:Mitogen-Activated Protein Kinase 12 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D048292:Mitogen-Activated Protein Kinase 13 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D013997:Time Factors; D020298:U937 Cells
D000943:Antigens, Differentiation; D007093:Imidazoles; D007527:Isoenzymes; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D048291:Mitogen-Activated Protein Kinase 12; D048292:Mitogen-Activated Protein Kinase 13; D002117:Calcitriol; C090942:4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole
FEBS Lett. 1996 Sep 2;392(3):209-14
8774846
Proc Soc Exp Biol Med. 1985 Jul;179(3):288-95
3858884
J Biol Chem. 1996 Feb 9;271(6):2886-91
8621675
J Cell Biochem. 2001 Apr 2-27;82(1):68-77
11400164
J Cell Biol. 1984 Feb;98(2):391-8
6319426
J Biol Chem. 1996 Jul 26;271(30):17920-6
8663524
Exp Cell Res. 2010 Feb 15;316(4):603-14
19945455
Int J Cancer. 1976 May 15;17(5):565-77
178611
Mol Cell Biol. 2005 May;25(9):3670-81
15831472
J Biol Chem. 2004 Jun 11;279(24):25345-52
15056660
Blood. 1979 Sep;54(3):713-33
288488
Cancer Treat Rep. 1985 Dec;69(12):1399-407
2416438
Cancer Res. 2006 Apr 15;66(8):4402-9
16618766
Hematol Oncol. 2010 Sep;28(3):124-32
19866452
Proc Natl Acad Sci U S A. 1981 Aug;78(8):4990-4
6946446
Crit Rev Clin Lab Sci. 2009;46(4):190-209
19650715
Biochemistry. 1998 Sep 29;37(39):13846-53
9753474
J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):47-55
16046262
Endocrinology. 2002 Jul;143(7):2508-14
12072382
Curr Opin Cell Biol. 1996 Apr;8(2):205-15
8791420
Leuk Res. 1995 Jan;19(1):65-72
7837819
Neurochem Res. 2000 Apr;25(4):527-31
10823586
J Biol Chem. 1993 Mar 5;268(7):5014-20
8095266
Cancer Res. 1999 May 1;59(9):2195-202
10232608
Curr Biol. 1998 Sep 24;8(19):1049-57
9768359
FEBS Lett. 2000 Apr 21;472(1):50-2
10781803
J Leukoc Biol. 1998 Sep;64(3):409-17
9738669
Anticancer Res. 2001 Jan-Feb;21(1A):499-504
11299787
Anticancer Agents Med Chem. 2010 Mar;10(3):186-95
20015009
J Biol Chem. 2002 Oct 4;277(40):37212-8
12149242
J Biol Chem. 2003 Jul 18;278(29):26715-21
12738796
Cytometry. 1992;13(8):795-808
1333943
Leuk Res. 2010 May;34(5):553-65
19811822
Pharmacol Ther. 1999 May-Jun;82(2-3):389-97
10454214
J Biol Chem. 1997 Sep 19;272(38):23668-74
9295308
Exp Cell Res. 2007 May 1;313(8):1722-34
17397830
Cell Signal. 2000 Jan;12(1):1-13
10676842
Biochim Biophys Acta. 2000 Oct 18;1502(2):207-23
11040446
J Cell Biochem. 2001;80(4):471-82
11169731
J Cell Biochem. 2003 Aug 15;89(6):1087-101
12898508
J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):195-202
16085411
Biochem Biophys Res Commun. 1999 Sep 24;263(2):528-36
10491326
Leukemia. 2005 Oct;19(10):1812-7
16107889
J Steroid Biochem Mol Biol. 2007 Jun-Jul;105(1-5):140-9
17583492
EMBO J. 1996 Dec 16;15(24):7026-35
9003778
Cell Signal. 2005 Dec;17(12):1572-7
15951157
Exp Cell Res. 2000 Aug 1;258(2):425-37
10896794
J Biol Chem. 1997 Nov 28;272(48):30122-8
9374491
Cancer Biol Ther. 2010 Aug 15;10(4):344-50
20543580
Cancer Res. 2004 Jan 1;64(1):370-7
14729647
Anal Biochem. 1987 Apr;162(1):156-9
2440339